Pulmonx Corporation Revenue and Competitors

Location

$276.9M

Total Funding

Estimated Revenue & Valuation

  • Pulmonx Corporation's estimated annual revenue is currently $44.5M per year.(i)
  • Pulmonx Corporation received $20.0M in venture funding in September 2014.
  • Pulmonx Corporation's estimated revenue per employee is $171,308
  • Pulmonx Corporation's total funding is $276.9M.
  • Pulmonx Corporation's current valuation is $1B. (January 2022)

Employee Data

  • Pulmonx Corporation has 260 Employees.(i)
  • Pulmonx Corporation grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M76-3%N/AN/A
#2
$8M32-6%N/AN/A
#3
$5M20-9%N/AN/A
#4
$8.5M346%N/AN/A
#5
$5.3M21-9%N/AN/A
#6
$49.7M1980%N/AN/A
#7
$12M48N/AN/AN/A
#8
$8.5M3421%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$56.8M181-1%$199.1MN/A
Add Company

Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. The Company's first commercial products address emphysema, a form of COPD (chronic obstructive pulmonary disease) and the largest unmet medical need in Pulmonology. With emphysema, breathing becomes increasingly more difficult as the disease progresses. Today in the U.S., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. Pulmonx has developed the Zephyr Endobronchial Valve (EBV) Therapy, a non-surgical, investigational approach to treating emphysema. The minimally invasive Zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. No surgery is involved in the simple, one-hour procedure. More than 25,000 Zephyr valves have been implanted outside the U.S. in the last 10 years. Clinical studies in Europe have shown that the majority of qualified patients who have the procedure see a significant improvement in lung function, exercise tolerance and quality of life. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema. Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States. CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.

keywords:Biotechnology

$276.9M

Total Funding

260

Number of Employees

$44.5M

Revenue (est)

8%

Employee Growth %

$1B

Valuation

N/A

Accelerator

Pulmonx Corporation News

2022-04-19 - Pulmonx (NASDAQ:LUNG) Upgraded to “Hold” by Zacks ...

According to Zacks, “Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive...

2022-04-17 - Pulmonx to Present at the Bank of America Securities 2022 ...

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx's Zephyr® Endobronchial...

2022-04-13 - Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally...

2021-01-28 - JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign

KNOXVILLE, Tenn., Jan. 28, 2021 /PRNewswire/ -- JTV®, the national jewelry retailer and broadcast network, is excited to announce its third annual Catch Your Breath® campaign, in partnership with Respiratory Health Association® (RHA) and co-sponsor Pulmonx® Corporation, to support the fight ag ...

2020-05-06 - Ally Bridge Group Leads Pulmonx’s $66mn Financing to Support Commercial Acceleration of the Zephyr Valve System

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$41.6M261-9%N/A
#2
$66.8M266-31%N/A
#3
$101.3M267-21%$162M
#4
$61.2M279-3%$96.3M
#5
$42.9M28518%$45M

Pulmonx Corporation Funding

DateAmountRoundLead InvestorsReference
2007-03-22$18.5MB1Article
2007-05-08$20.4MB-1De Novo Ventures, Latterell Venture PartnersArticle
2008-08-18$3.0MUndisclosedArticle
2010-01-20$11.5MUndisclosedDe Novo Ventures, Latterell Venture PartnersArticle
2010-02-23$32.0MUndisclosedArticle
2014-04-02$10.0MUndisclosedArticle
2014-09-18$20.0MUndisclosedOxford Finance LLCArticle